Joint Venture

EMA approves ViiV's Tivicay

The GlaxoSmithKline-Pfizer-Shionogi joint venture scored an FDA approval in August.

BMS breaks free of diabetes

BMS breaks free of diabetes

By

BMS is giving up its stake of the AstraZeneca diabetes joint venture for $2.7 billion up front, and future milestone payments.

Business briefs: Glaxo, Teva, Johnson & Johnson

Glaxo shakes up China division, Teva and Lonza break up their biosimilars pact, and FDA's breakthrough designation speeds review but not international and payer uptake.

Business Briefs: India Health Ministry, Takeda, Sucampo and Pfizer Consumer Care

India bans sales of Takeda's Actos; Takeda make a $10-million milestone payment to Sucampo; and Pfizer Consumer Care says Advil is the official pain reliever of Tough Mudder.

McCann launches Hispanic health marketing unit

McCann launches Hispanic health marketing unit

By

Interpublic's McCann HumanCare and Casanova Pendrill hope to sell pharmas on deeper engagement with Hispanic audiences through a joint venture dubbed HumanCareHSP

Company news: Time, Takeda, Amylin, PwC

Time Inc. targeted media brand focuses on pharma; Takeda and Amylin call it quits on obesity partnership; PricewaterhouseCoopers builds regulatory intelligence unit

Enbrel reps risk layoff, as Pfizer calls early end to US selling

Enbrel reps risk layoff, as Pfizer calls early end to US selling

By

When Pfizer's US Enbrel sales force gives way to Amgen's in July, reps risk layoff if they don't get picked up by Amgen or re-assigned to Pfizer's new JAK inhibitor.

Teva, P&G partner to form global OTC behemoth

By

Teva is partnering with Procter & Gamble in an OTC drug marketing joint venture that will boast annual sales of more than $1 billion -- and which could ultimately be worth four times that, the companies say.

Email Newsletters